Roche Holding AG
RHHBF
Market Cap$261.18B
Close$
Earnings Call Q2 2024
July 25, 2024 - AI Summary
Group sales increased by 8% in the first half of the year, excluding COVID impact.
Pharma division saw strong growth in base business with an 8% increase in sales.
Diagnostics division also experienced solid growth with a 9% increase in sales.
Exclusive for Stockcircle Pro members
Sign up
$747.42
116.4% upside
Current Fair Value
116.4% upsideUndervalued by 116.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $261.18 Billion |
|---|---|
| Enterprise Value | $294.02 Billion |
| Dividend Yield | $10.97477 (3.56093979441997%) |
| Earnings per Share | $10.39 |
| Beta | 0.22 |
| Outstanding Shares | 802,307,692 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 26.18 |
|---|---|
| PEG | -212.54 |
| Price to Sales | 2.7 |
| Price to Book Ratio | 7.68 |
| Enterprise Value to Revenue | 2.84 |
| Enterprise Value to EBIT | 9.97 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 1.25 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Roche Holding AG
CEO: Severin Schwan Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ...